Akoya Biosciences
High-parameter tissue analysis platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 29 % | 36 % | 29 % | (15 %) | - | 19 % | 2 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (60 %) | (79 %) | (46 %) | (39 %) | (51 %) | (24 %) | (33 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (78 %) | (94 %) | (66 %) | (68 %) | (56 %) | (34 %) | (39 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 29 % | 31 % | 23 % | 24 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Akoya Biosciences, accessible at akoyabio.com, is a pioneering company in the field of spatial biology. The company specializes in high-throughput multiplex imaging solutions, which allow researchers to explore spatial biomarkers within the tissue microenvironment at a single-cell resolution. This technology is crucial for understanding complex biological systems and diseases, particularly in the realm of cancer research.
Akoya's primary clients include academic institutions, pharmaceutical companies, and clinical research organizations. These clients utilize Akoya's technology to advance their research in areas such as oncology, immunology, and neuroscience. The company operates in the biotechnology and life sciences market, which is characterized by rapid innovation and significant investment in research and development.
The business model of Akoya Biosciences revolves around the sale of its comprehensive imaging solutions, which include instruments, panels, and software. These products enable the analysis of up to 8 protein markers and 80 slides per day, providing a high-throughput solution for researchers. Akoya generates revenue through the direct sale of these products, as well as through service contracts and partnerships with pharmaceutical companies and academic institutions.
Akoya's leadership team includes experts with extensive experience in research, development, and business operations. For example, Dr. Julia Kennedy Darling, the Director of Research Development, has a strong background in chemistry and cancer research, while Cliff Hoyt, the Vice President of Translational Scientific Affairs, has a deep understanding of quantitative pathology and multiplexed staining methods.
In summary, Akoya Biosciences is at the forefront of spatial biology, providing cutting-edge imaging solutions that enable researchers to gain deeper insights into the tissue microenvironment. The company's innovative products and strategic partnerships position it well in the competitive biotechnology market.
Keywords: spatial biology, multiplex imaging, biomarkers, tissue microenvironment, single-cell resolution, cancer research, biotechnology, life sciences, high-throughput, research solutions.